Lexaria Bioscience Corp. LEXX
4.54 USD +0.05 (+1.11%)
At closeNov 9, 2026, 4:00 PM EST
4.54 0.00 0.00%
After hours · Nov 9, 4:00 PM ET
4.41 Day range 4.69
2.43 52-week range 21.60
- YTD
- -50.97%
- 1 year
- -70.90%
News
benzinga.com Lexaria Bioscience Strikes Agreement With Undisclosed Pharma Firm To Investigate Lexaria's DehydraTECH Technology With One, More PharmCo Modules Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that it has entered into an Agreement with an unnamed pharmaceutical…
thenewswire.com Lexaria Enters a New Pharmaceutical Agreement for DehydraTECH Third pharmaceutical company relationship entered Kelowna, British Columbia – November 4, 2026 – TheNewswire - Lexaria Bioscience Corp. (Nasdaq: LEXX) (the “ Company ” or “ Lexaria ”), a global…
benzinga.com Lexaria Bioscience Completes Enrollment And Continues Dosing On Schedule In Two Oral Semaglutide Pilot Study Comparing DehydraTECH Formulations To Wegovy Tablets Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, reports that full enrollment has been reached and dosing continues on schedule with
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers Silexion Therapeutics (NASDAQ:SLXN) shares moved upwards by 11.0% to $0.17 during Friday's after-market session. The company's market cap stands at $2.4 million. Lexaria Bioscience…
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session Gainers Alaunos Therapeutics (NASDAQ:TCRT) stock rose 34.9% to $2.94 during Thursday's after-market session. The market value of their outstanding shares is at $7.6 million. Senti Biosciences…- benzinga.com Lexaria Bioscience Announces Results From Animal Study GLP-1-A26-1 Evaluating Both DehydraTECH-CBD Compositions And DehydraTECH-Semaglutide; Unfortunately, The DHT-SEMA Concentrations In Brain Tissue Were All At Levels Below The Lower Limit Of Quantitation Of The Bioassay Utilized In This Study Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to provide the following results from animal study GLP-1-A26-1 (the
- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers Valneva (NASDAQ:VALN) shares rose 20.6% to $7.09 during Wednesday's after-market session. The company's market cap stands at $555.6 million. Profound Medical (NASDAQ:PROF) stock rose 16.98%…
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session Gainers Prime Medicine (NASDAQ:PRME) shares increased by 13.0% to $3.47 during Thursday's after-market session. The market value of their outstanding shares is at $567.7 million. Onconetix…- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session Gainers Alaunos Therapeutics (NASDAQ:TCRT) shares moved upwards by 30.0% to $2.08 during Thursday's after-market session. The company's market cap stands at $3.2 million. cbdMD (AMEX:YCBD) stock…
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Circle8 Group (NASDAQ:CIRC) stock moved upwards by 14.6% to $0.57 during Monday's after-market session. The company's market cap stands at $50.2 million. Eocene (NASDAQ:EOCN) shares rose…- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Basel Medical Group (NASDAQ:BMGL) shares moved upwards by 59.8% to $7.32 during Monday's regular session. Scinai Immunotherapeutics (NASDAQ:SCNI) stock increased by 45.18% to $2.41. The…
- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Tenon Medical (NASDAQ:TNON) stock moved upwards by 76.4% to $4.3 during Thursday's regular session. The market value of their outstanding shares is at $1.6 million. AEON Biopharma (AMEX:AEON)…
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers Opus Genetics (NASDAQ:IRD) shares increased by 31.7% to $5.71 during Wednesday's regular session. The company's market cap stands at $361.0 million. bioAffinity Technologies (NASDAQ:BIAF)…
- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session Gainers InnovAge Holding (NASDAQ:INNV) shares increased by 10.8% to $11.65 during Tuesday's after-market session. The company's market cap stands at $1.4 billion. The company's, Q4 earnings came out…
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers Indaptus Therapeutics (NASDAQ:INDP) stock increased by 46.7% to $1.79 during Tuesday's regular session. The market value of their outstanding shares is at $162.5 million. PDS Biotechnology…
benzinga.com Crude Oil Gains 1.5%; ABM Posts Upbeat Q3 Earnings U.S. stocks fell Tuesday as health care lagged, while energy gained. ABM beat estimates; oil rose, and several biotech shares surged or plunged.
benzinga.com Dow Tumbles 450 Points; US Small Business Sentiment Declines In August U.S. stocks fell Tuesday, led by a 450-point Dow drop; health care slid while energy rose. NFIB optimism weakened, oil and copper gained.- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers iSpecimen (NASDAQ:ISPC) stock increased by 22.7% to $1.89 during Tuesday's pre-market session. The company's market cap stands at $3.8 million. Bluejay Diagnostics (NASDAQ:BJDX) shares moved…
benzinga.com Lexaria Bioscience Announces Australian Tax Office Pays AU$3.667M In Tax Rebate To Co. Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, is pleased to announce that it has received a cash rebate of AUD$3,666,611.98…
benzinga.com Lexaria Bioscience Completes Blood Plasma Pharmacokinetic Bioanalysis Testing In Its 2026 Animal Study 2 Evaluating Oral Delivery Of 2 Next-Generation GLP-Drugs, Amycretin And Retatrutide, In A Total Of 18 Different Study Arms In Dogs Following Use Of Its DehydraTECH Drug Delivery Platform Proprietary DehydraTECH 3.0 amycretin tablet formulation more than doubled absolute bioavailability compared to a leading industry studyProprietary DehydraTECH 3.0 retatrutide tablet formulation…- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers INVO Fertility (NASDAQ:IVF) stock moved upwards by 13.1% to $1.73 during Monday's after-market session. The company's market cap stands at $1.7 million. The company's, Q2 earnings came out…
benzinga.com Lexaria Bioscience Stock Rallies Thursday: What Investors Need to Know Lexaria Bioscience shares are surging Thursday afternoon after announcing a new Material Transfer Agreement with Hong Kong-listed PegBio.- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Liminatus Pharma (NASDAQ:LIMN) stock increased by 48.4% to $0.16 during Thursday's regular session. The market value of their outstanding shares is at $7.2 million. BeyondSpring (NASDAQ:BYSI)…
benzinga.com Lexaria Bioscience Enters Material Transfer Agreement With Pegbio To Investigate LEXX's DehydraTECH Technology With A Proprietary Pegbio Molecule Under Development For The GLP-1 Industry Today's announcement is separate from, and has no relationship with, Lexaria's pre-existing Material Transfer Agreement with another pharmaceutical company.The MTA details the conditions under which…- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session Gainers ENDRA Life Sciences (NASDAQ:NDRA) shares rose 10.8% to $5.94 during Tuesday's after-market session. The market value of their outstanding shares is at $6.2 million. Apimeds Pharmaceuticals…
- benzinga.com Lexaria Bioscience Q3 EPS $(0.08) Beats $(0.09) Estimate Lexaria Bioscience (NASDAQ:LEXX) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.09) by 0 percent. This is a 61.9 percent increase over losses of…
- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers OSR Health (NASDAQ:OSRH) stock increased by 7.2% to $0.33 during Wednesday's after-market session. The company's market cap stands at $11.0 million. BioRestorative Therapies (NASDAQ:BRTX)…
benzinga.com Lexaria Bioscience Announces It Began Dosing On June 14 In Its Human Study GLP-1-H26-7 Evaluating Two Oral DehydraTECH-Semaglutide Compositions Against Wegovy Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that dosing began on schedule on June 14th with Human Pilot Study #7- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
benzinga.com Lexaria Bioscience Receives Ethics Approval For Human GLP-1 Study Comparing Oral DehydraTECH-Semaglutide Formulations To Wegovy, With Dosing Expected To Begin In Mid-June Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, is pleased to announce that ethics approval has been received from an…- benzinga.com Lexaria Bioscience Advances Human Study Of DehydraTECH-Semaglutide Versus Wegovy Tablets Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, provides this update on Human Pilot Study #7 (GLP-1-H26-7) that will evaluate…
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
- benzinga.com Lexaria Bioscience Extends Pharma Partnership Through 2026 To Advance GLP-1 Research And DehydraTECH Licensing Potential Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, provides this update on the Material Transfer Agreement ("MTA") originally…
- benzinga.com Lexaria Bioscience Engages The Contract Research Organization To Execute And Report On Its 2026 Animal Study #2 That Will Evaluate A Number Of Formulation Enhancements With Two Next-Generation GLP-1 Drugs In Animals Lexaria Bioscience Corp. (NASDAQ:LEXX), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce the engagement of the contract research organization…
- benzinga.com Lexaria Engages CRO To Execute, Report On 2026 Animal Study GLP-1-A26-1 Evaluating Formulation Enhancements Using Both DHT-Sema GLP-1 And DHT-CBD Compositions To Explore Potential For Additional Improved Performance And Stake New IP Claims Lexaria Bioscience Corp. (NASDAQ:LEXX), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce the engagement of the contract research organization…
benzinga.com Lexaria Bioscience Q2 EPS $(0.06) Beats $(0.11) Estimate, Sales $20.000K Miss $100.000K Estimate Lexaria Bioscience (NASDAQ:LEXX) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.11) by 45.45 percent. This is a 60 percent increase over losses of…- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
- benzinga.com Lexaria Bioscience To Initiate New, Five-Week Human Clinical Study To Evaluate 2 Oral DehydraTECH-Semaglutide Compositions Against Wegovy Lexaria Bioscience Corp. (NASDAQ:LEXX), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce the engagement of the contract research organization ("CRO")…
- benzinga.com Lexaria Bioscience Receives 5 New Patents Including 2 For Diabetes Treatment Utilizing GLP-1 Drugs Lexaria Bioscience Corp. (NASDAQ:LEXX), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to provide this update on additional new intellectual property ("IP")…
- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
- benzinga.com Lexaria Bioscience Launches 2026 R&D Program With Human And Animal GLP-1 Studies To Expand Drug Delivery IP And Business Opportunities Exciting new human and animal studies designed to enhance business opportunitiesKELOWNA, BC / ACCESS Newswire / March 4, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX), (the "Company" or "Lexaria"), a…
- benzinga.com Lexaria Bioscience Results From Human Pilot Study, Comparing DehydraTECH-liraglutide Capsules To Injected Saxenda Branded Liraglutide, Achieves 22.7% Reduction In Adverse Events With DHT-LIR As Compared To SAX-LIR Lexaria Bioscience Corp. (NASDAQ:LEXX), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce final results from Human Pilot Study #5 (GLP-1-H25-5) (the…
benzinga.com Why Bark Shares Are Trading Higher By 20%; Here Are 20 Stocks Moving Premarket - benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
- benzinga.com Lexaria Bioscience Reports Final Phase 1b GLP-1-H24-4 Results Showing DHT-Semaglutide Demonstrates Comparable Or Improved Safety, Tolerability And Body Composition vs. Rybelsus Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides the following additional secondary and exploratory endpoint…
benzinga.com Capital One Financial To Rally More Than 24%? Here Are Top Analyst Forecasts For Friday - benzinga.com HC Wainwright & Co. Maintains Buy on Lexaria Bioscience, Lowers Price Target to $1.5 HC Wainwright & Co. analyst Yi Chen maintains Lexaria Bioscience (NASDAQ:LEXX) with a Buy and lowers the price target from $4 to $1.5.
benzinga.com Lexaria Says Oral GLP-1 Cuts Side Effects Nearly 50% Versus Novo Nordisk's Rybelsus Lexaria says its oral GLP-1 cut total adverse events nearly 48% versus Novo's Rybelsus, with comparable HbA1c results in a Phase 1b study.- benzinga.com Lexaria Bioscience's DehydraTECH-Semaglutide Shows 48% Reduction In Overall Side Effects And 55% Reduction In Gastrointestinal Side Effects Compared To Rybelsus In Phase 1b Study; Says Recent Financings Support New 2026 Development Opportunities DehydraTECH-semaglutide reduced overall side effects by 48% as compared to Rybelsus®DehydraTECH-semaglutide reduced gastrointestinal side effects by 55% as compared to Rybelsus®Recent financings…
- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session